Prometheus and progenitors
Anna Mae Diehl – 24 December 2014
Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus–coinfected patients with mild fibrosis in the short term
Juan Macías, María Mancebo, Manuel Márquez, Dolores Merino, Francisco Téllez, Antonio Rivero, Miguel A. von Wichmann, Luis F. López‐Cortés, Nicolás Merchante, Jesús Santos, Miguel Raffo, Montserrat Pérez‐Pérez, Ángela Camacho, Jose A. Iribarren, Juan A. Pineda – 24 December 2014 – Liver fibrosis is used to make decisions about the timing of therapy against hepatitis C virus (HCV) in routine clinical practice, which should be based on the short‐term likelihood of liver decompensations.
Reply
Patrick Starlinger, Christine Brostjan, Thomas Gruenberger – 24 December 2014
Farnesoid X receptor–induced lysine‐specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity
Young‐Chae Kim, Sungsoon Fang, Sangwon Byun, Sunmi Seok, Byron Kemper, Jongsook Kim Kemper – 24 December 2014 – Bile acids (BAs) function as endocrine signaling molecules that activate multiple nuclear and membrane receptor signaling pathways to control fed‐state metabolism. Since the detergent‐like property of BAs causes liver damage at high concentrations, hepatic BA levels must be tightly regulated.
Evidence against a role of serotonin in liver regeneration in humans
Edris M. Alkozai, Martijn van Faassen, Ido P. Kema, Robert J. Porte, Ton Lisman – 24 December 2014
Ezrin finds its groove in cholangiocytes
Laura Fouassier, Romina Fiorotto – 24 December 2014
Central obesity induces a greater risk of hepatocellular carcinoma than general obesity
Qing Pang, Jing Yao Zhang, Kai Qu, Si Dong Song, Su Shun Liu, Chang Liu – 24 December 2014
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
Yunching Chen, Rakesh R. Ramjiawan, Thomas Reiberger, Mei R. Ng, Tai Hato, Yuhui Huang, Hiroki Ochiai, Shuji Kitahara, Elizabeth C. Unan, Tejaswini P. Reddy, Christopher Fan, Peigen Huang, Nabeel Bardeesy, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda – 20 December 2014 – Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits.
Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans
Miklos Z. Molnar, Hazem M. Alhourani, Barry M. Wall, Jun L. Lu, Elani Streja, Kamyar Kalantar‐Zadeh, Csaba P. Kovesdy – 20 December 2014 – An estimated 4 million Americans have been exposed to the hepatitis C virus (HCV). The risks of incident and progressive chronic kidney disease and of mortality in patients with normal kidney function infected with HCV are unclear.
Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease
Jeffrey B. Schwimmer, Michael S. Middleton, Cynthia Behling, Kimberly P. Newton, Hannah I. Awai, Melissa N. Paiz, Jessica Lam, Jonathan C. Hooker, Gavin Hamilton, John Fontanesi, Claude B. Sirlin – 20 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children. In order to advance the field of NAFLD, noninvasive imaging methods for measuring liver fat are needed. Advanced magnetic resonance imaging (MRI) has shown great promise for the quantitative assessment of hepatic steatosis but has not been validated in children.